A Randomized, Placebo-Controlled, Double-Blind Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ITI-214 in Patients With Idiopathic Parkinson's Disease
Phase of Trial: Phase I/II
Latest Information Update: 10 May 2019
Price : $35 *
At a glance
- Drugs ITI 214 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Intra-Cellular Therapies
- 18 Dec 2018 Status changed from recruiting to completed.
- 23 Oct 2018 According to an Intra-Cellular Therapies media release, additional results will be presented at future meetings.
- 23 Oct 2018 According to an Intra-Cellular Therapies media release, results were presented at the 2018 American Neurological Association Annual Meeting 2018.